MaxCyte Inc (MXCT)

Currency in USD
1.260
-0.030(-2.33%)
Closed·
1.320+0.060(+4.76%)
·
MXCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2601.310
52 wk Range
1.2505.200
Key Statistics
Prev. Close
1.29
Open
1.3
Day's Range
1.26-1.31
52 wk Range
1.25-5.2
Volume
449.48K
Average Volume (3m)
911.71K
1-Year Change
-74.4939%
Book Value / Share
1.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MXCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.240
Upside
+474.60%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

MaxCyte Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

MaxCyte Inc Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte Inc Earnings Call Summary for Q2/2025

  • MaxCyte Q2 revenue missed forecast at $8.5M, EPS at -$0.12; stock dipped 0.97% to $2.04, near 52-week low
  • 2025 core revenue guidance lowered to flat or down 10%; company projects $155M cash by year-end
  • Strong cash position of $165.2M with no debt; gross margin declined to 82% from 86% year-over-year
  • Focus on operational efficiency and Asia Pacific growth; new platform launch planned for late 2025
  • CEO remains optimistic about MaxCyte's position in cell and gene therapy market despite short-term challenges
Last Updated: 2025-08-07, 03:36 a/m
Read Full Transcript

Compare MXCT to Peers and Sector

Metrics to compare
MXCT
Peers
Sector
Relationship
P/E Ratio
−2.9x−1.1x−0.6x
PEG Ratio
0.12−0.040.00
Price/Book
0.7x2.8x2.6x
Price / LTM Sales
3.9x2.8x3.4x
Upside (Analyst Target)
-92.7%39.6%
Fair Value Upside
Unlock7.7%5.2%Unlock

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.240
(+474.60% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Hold---DowngradeAug 11, 2025
William Blair
Hold---DowngradeAug 07, 2025
Stephens
Buy6.00+376.19%-New CoverageJul 22, 2025
BTIG
Buy5.00+296.83%6.00MaintainMay 08, 2025
Stifel
Buy9.00+614.29%11.00MaintainMar 12, 2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.12 / -0.1133
Revenue / Forecast
6.83M / 8.63M
EPS Revisions
Last 90 days

MXCT Income Statement

People Also Watch

0.831
ADV
+1.47%
20.16
ZBIO
+1.15%
20.000
SPNT
-1.96%
18.400
EBRO
+0.55%
26.120
HRTG
+1.04%

FAQ

What Is the MaxCyte (MXCT) Stock Price Today?

The MaxCyte stock price today is 1.260

What Stock Exchange Does MaxCyte Trade On?

MaxCyte is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for MaxCyte?

The stock symbol for MaxCyte is "MXCT."

What Is the MaxCyte Market Cap?

As of today, MaxCyte market cap is 134.41M.

What Is MaxCyte's Earnings Per Share (TTM)?

The MaxCyte EPS (TTM) is -0.43.

When Is the Next MaxCyte Earnings Date?

MaxCyte will release its next earnings report on Mar 17, 2026.

From a Technical Analysis Perspective, Is MXCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has MaxCyte Stock Split?

MaxCyte has split 0 times.

How Many Employees Does MaxCyte Have?

MaxCyte has 114 employees.

What is the current trading status of MaxCyte (MXCT)?

As of Jan 19, 2026, MaxCyte (MXCT) is trading at a price of 1.260, with a previous close of 1.290. The stock has fluctuated within a day range of 1.260 to 1.310, while its 52-week range spans from 1.250 to 5.200.

What Is MaxCyte (MXCT) Price Target According to Analysts?

The average 12-month price target for MaxCyte is USD7.24, with a high estimate of USD9 and a low estimate of USD5.72. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +474.60% Upside potential.

What Is the MXCT After Hours Price?

MXCT's last after hours stock price is 1.320, the stock has decreased by 0.060, or 4.760%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.